LEADER 00000cam a2200781 i 4500 
001    ocn229431501 
003    OCoLC 
005    20160527040600.4 
006    m     o  d         
007    cr un||||||||| 
008    140806s2001    dcua    obt   000 0 eng   
016 7  101645010|2DNLM 
019    48910974|a58591999|a70905601|a488310950|a488388146
       |a560394575|a646728082|a722333825|a728014358|a744950479
       |a793587768|a804921642|a814297238 
020    0309579872 
020    9780309579872 
020    1280248041 
020    9781280248047 
035    (OCoLC)229431501|z(OCoLC)48910974|z(OCoLC)58591999
       |z(OCoLC)70905601|z(OCoLC)488310950|z(OCoLC)488388146
       |z(OCoLC)560394575|z(OCoLC)646728082|z(OCoLC)722333825
       |z(OCoLC)728014358|z(OCoLC)744950479|z(OCoLC)793587768
       |z(OCoLC)804921642|z(OCoLC)814297238 
037    |b00017961 
040    DNLM|beng|erda|epn|cNLM|dCOO|dINM|dN$T|dYDXCP|dCOF|dVAM
       |dPSM|dDKDLA|dMERUC|dCCO|dE7B|dFVL|dNLGGC|dIDEBK|dS4S
       |dOCLCQ|dOCLCO 
042    pcc 
043    n-us--- 
049    RIDW 
050  4 RA644.A6|bC4 2001eb 
072  7 MED|x022090|2bisacsh 
072  7 HEA|x039040|2bisacsh 
082 04 616.956|222 
090    RA644.A6|bC4 2001eb 
245 00 CDC anthrax vaccine safety & efficacy research program :
       |binterim report /|cInstitute of Medicine. 
246 10 CDC anthrax vaccine safety and efficacy research program 
264  1 Washington, DC :|bNational Academy Press,|c[2001] 
300    1 online resource (1 PDF file (xii, 45 pages)) :
       |billustrations 
336    text|btxt|2rdacontent 
337    computer|bc|2rdamedia 
338    online resource|bcr|2rdacarrier 
347    text file|2rdaft 
500    Title from PDF title page. 
500    "Prepublication Copy, Uncorrected Proofs"--PDF title page.
504    Includes bibliographical references. 
505 0  Cover -- Copyright -- Table of Contents -- Preface -- 
       Acknowledgments -- REVIEWERS -- Executive Summary -- 
       PROJECT-SPECIFIC FINDINGS AND RECOMMENDATIONS -- NCID-
       Directed Projects in the Research Program -- NIP-Directed 
       Projects of the Research Program -- 1 Introduction and 
       Background -- ANTHRAX DISEASE AND PREVENTION -- Anthrax 
       Disease -- Anthrax Vaccine -- VACCINE RELATED ADVERSE 
       EVENTS -- POLICY CONTEXT OF REPORT -- Anthrax Vaccination 
       Policy -- CDC'S REPONSE TO CONGRESS -- 2 Interim Findings 
       and Recommendations -- NCID RESEARCH ACTIVITIES -- Part A:
       Clinical Trial -- Part B: Non-human Primate Dose-Ranging 
       and Challenge Study -- Part C: Assays of Immunologic 
       Correlates of Protection -- NIP RESEARCH ACTIVITIES -- 
       Knowledge, Attitudes, and Beliefs of Military Personnel 
       about the Anthrax Vaccine -- Knowledge, Attitudes, and 
       Beliefs of Vaccine Providers about VAERS Reporting -- Data
       Mining Using the VAERS Database -- Meta-Analysis of 
       Existing Studies on the Anthrax Vaccine -- REFERENCES -- 
       ACRONYMS -- Appendix A Study Activities. 
520 3  Anthrax in its inhalational form is a deadly but very rare
       manifestation of infection with a common organism, 
       Bacillus anthracis. Anthrax spores are very stable, a 
       characteristic that makes possible their delivery as a 
       weapon of biological warfare, and examples of weapons 
       development efforts using anthrax are well known. It is 
       important to protect the men and women in our armed 
       services to the greatest extent possible. The Department 
       of Defense (DoD) established the Anthrax Vaccine 
       Immunization Program (AVIP) in order to do so; however, 
       some parties have raised questions about the safety and 
       even the efficacy of the vaccine. As a result, the DoD is 
       sponsoring an Institute of Medicine (IOM) study of the 
       safety and efficacy of the vaccine, and Congress has 
       instructed the Centers for Disease Control and Prevention 
       (CDC) to conduct further safety and efficacy research. The
       CDC contracted with the IOM to review their research 
       program for completeness and appropriateness. This 
       document is an interim report of the Committee to Review 
       the CDC Anthrax Vaccine Safety and Efficacy Research 
       Program, and reflects only a preliminary review of a 
       program still in development. 
536    Support for this project was provided by the Centers for 
       Disease Control and Prevention, Department of Health and 
       Human Services (Contract No. 200-2000-00629). The views 
       presented in this report are those of the Institute of 
       Medicine Committee to Review the CDC Anthrax Vaccine 
       Safety and Efficacy Research Program and are not 
       necessarily those of the funding agencies. 
588 0  Version viewed December 23, 2014. 
590    eBooks on EBSCOhost|bEBSCO eBook Subscription Academic 
       Collection - North America 
610 20 Centers for Disease Control and Prevention (U.S.)|0https:/
       /id.loc.gov/authorities/names/no93011529 
610 27 Centers for Disease Control and Prevention (U.S.)|2fast
       |0https://id.worldcat.org/fast/686437 
650  0 Anthrax|xVaccination.|0https://id.loc.gov/authorities/
       subjects/sh85005564 
650  0 Vaccines|0https://id.loc.gov/authorities/subjects/
       sh85141718|xEffectiveness.|0https://id.loc.gov/authorities
       /subjects/sh00005832 
650  0 Vaccines|0https://id.loc.gov/authorities/subjects/
       sh85141718|xSafety measures.|0https://id.loc.gov/
       authorities/subjects/sh00007912 
650  7 Anthrax|xVaccination.|2fast|0https://id.worldcat.org/fast/
       810166 
650  7 Vaccines.|2fast|0https://id.worldcat.org/fast/1163573 
650  7 Vaccines|xSafety measures.|2fast|0https://id.worldcat.org/
       fast/1163585 
650 12 Anthrax Vaccines.|0https://id.nlm.nih.gov/mesh/D022122 
650 12 Anthrax|xprevention & control.|0https://id.nlm.nih.gov/
       mesh/D000881Q000517 
651  2 United States.|0https://id.nlm.nih.gov/mesh/D014481 
650 22 Drug Evaluation.|0https://id.nlm.nih.gov/mesh/D004341 
650 22 Program Evaluation.|0https://id.nlm.nih.gov/mesh/D015397 
655  4 Electronic books. 
655  7 Technical reports.|2lcgft|0https://id.loc.gov/authorities/
       genreForms/gf2015026093 
655  7 Technical reports.|2fast|0https://id.worldcat.org/fast/
       1941336 
710 2  Institute of Medicine (U.S.).|bCommittee to Review the CDC
       Anthrax Vaccine Safety and Efficacy Research Program,
       |0https://id.loc.gov/authorities/names/no2003014658
       |eauthor. 
856 40 |uhttps://rider.idm.oclc.org/login?url=http://
       search.ebscohost.com/login.aspx?direct=true&scope=site&
       db=nlebk&AN=123516|zOnline eBook. Access restricted to 
       current Rider University students, faculty, and staff. 
856 42 |3Instructions for reading/downloading this eBook|uhttp://
       guides.rider.edu/ebooks/ebsco 
901    MARCIVE 20231220 
948    |d201606016|cEBSCO|tebscoebooksacademic|lridw 
994    92|bRID